Notably, knockdown of DDX11 in PEO1 and Capan-1 sensitive (S) as well as resistant (R) clones rendered the BRCA2-mutated tumor cells sensitive to olaparib (Fig. 6 C and D). This evidence concerns the gene BRCA2 and neoplasm.